期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氯吡格雷抵抗的临床处理 被引量：4

Clinical Strategies for Clopidogrel Resistance
下载PDF
导出
摘要 急性冠状动脉综合征的患者尽管接受了标准剂量的氯吡格雷治疗,仍有部分患者发生缺血性心血管事件,称为氯吡格雷抵抗。氯吡格雷抵抗引起的广泛关注使个体化抗血小板药物成为这些患者改善预后的治疗策略。在遗传学检测的辅助下,新型P2Y12受体拮抗剂普拉格雷、替卡格雷和坎格雷拉以及糖蛋白Ⅱb/Ⅲa受体拮抗剂和高剂量氯吡格雷是可能的应对措施。就现有的临床试验研究证据对氯吡格雷抵抗患者的个体化治疗做一综述。 Despite providing a standard dose of clopidogi-el to patients with acute coronary disease, cardiovascular ischemic events still occurred in some of them thereby indicating a resistance to clopidorel. As elopidogrel resistance increases, healthcare professionals are seeking out tailored antiplatelet therapies to improve clinical outcomes. Novel inhibitors of the P2Y12 receptor such as prasugrel, ticagrelor and cangrelor, as well as glycoprotein Ⅱb/Ⅲa receptor inhibitors and higher doses of clopidogrel with the assistance of genetic testing are probable ways to overcome clopidorel resistance. This article reviews currently available evidence of clinical trials and optimal clinical strategies for individual patients with clopidogrel resistance.
作者 王婧 袁晋青
机构地区 北京协和医学院中国医学科学院北京阜外心血管病医院
出处 《心血管病学进展》 CAS 2012年第1期24-27,共4页 Advances in Cardiovascular Diseases
关键词 氯吡格雷 氯吡格雷抵抗 普拉格雷 替卡格雷 clopidogrel clopidogrel resistance prasugrel ticagrelor
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献28

  • 1Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirinand fibrinolytic therapy for myocardial infarction with ST-segment elevation[ J ]. N Engl J Med, 2005, 352(12) : 1179-1189.
  • 2Mehta SR, Yusuf S. Shortand long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention[ J]. J Am Coil Cardiol, 2003, 41 (d suppl S) : 79S-88S.
  • 3Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement[J]. Thromb Haemost, 2003, 89(5): 783-787.
  • 4Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenfing: response variability, drug resistance, and the effect of pretreatment platelet reactivity[J]. Circulation, 2003, 107(23): 2908-2913.
  • 5Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the .evidence[J]. J Am Coil Cardiol, 2005, 45(8) : 1157-1164.
  • 6Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome[J]. JAMA, 2009, 301(9) : 937-944.
  • 7Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel [ J ]. CMAJ, 2009, 180(7) : 713-718.
  • 8Olonoghue ML, Brannwald E, Antnmn EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor : an analysis of two randomised trials [ J ]. Lancet, 2009, 374 ( 9694 ) : 989-997.
  • 9Bhatt D. Clopidogrel and the optimization of gastro-intestinal events trial ( COGENT trial) [ R ]. San Francisco, CA : Transcatheter Cardiovascular Therapeutics meeting ( TCT 2009), September 24, 2009.
  • 10Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused up date of the guidelines for the management of patients with unstable angina/ Non-ST-Elevation myocardial infarction (updating the 2007 guideline ) : a re port of the American College of Cardiology foundation/American Heart Associa tion task force on practice guidelines[ Jl. Circulation, 2011, 123(18) : 2022-2060.

同被引文献36

  • 1陈灏珠,钟南山,陆再英.内科学[M].第8版.北京:人民卫生出版社,2013:3.
  • 2Mortality : Cardiovascular diseases and diabetes, deaths per 100,000 Data by country [ DB/OL ] . http://apps, who. int/gho/data/node, main. A865 lang = en.
  • 3David H. Fitchett, Pierre Theroux, James M. Brophy, et al. Assessment and Management of Acute Coronary Syndromes (AES) : A Canadian Perspective on Current Guideline-Recommended Treatment-Part 1: Non-ST- Segment Elevation ACS[J]. Canadian Journal of Cardiology, 2011, (27) : S387-S401.
  • 4Crespin D J, Federspiel J J, Biddle A K, et al. Ticagrelor versus genotype- driven antiplatelet therapy for secondary pre,Jention after acute coronary syn- drome: a cost-effectiveness analysis [ J ]. Value in Health, 2011,14 (4) : 483-491.
  • 5Baigem C, Blackwell L, Collins R, et al. Aspirin in the primary and sec- ondary prevention of vascular disease : collaborative meta-analysis of individ- ual participant data from randomized trials[J]. Lancet, 2009,37(3) :1849-1860.
  • 6Eindgren P, Jsnsson B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the cure trial [Jl. Journal of internal medicine, 2004,255(5) : 562-570.
  • 7James S, Akerblom A, Cannon C P,et al. Comparison of tieagrelor, the first reversible oral P2Y < sub > 12 < sub > receptor antagonist, with clopidogrel in patients with acute coronary syndromes : Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Out- comes (PLATO) trial [ J ] . American heart journal, 2009,157 ( 4 ) : 599-605.
  • 8Craig I. Coleman, Brendan L. Limone. Cost-Effectiveness of Universal and Platelet Reactivity Assay-Driven Antiplatelet Therapy in Acute Coronary Syn- drome[ Jl. Am J Cardiol,2013 ,112 :355-362.
  • 9Jaime Latom-Perez, Eva de Miguel Balsa, Lourdes Betegen, et al. Using Triple Antiplatelet Therapy in Patients with Non-ST Elevation Acute Coronary Syndrome Managed lnvasively: A Cost-Effectiveness Analysis[ J ]. Val- ue in Health, 2008,11 ( 5 ) : 853 -861.
  • 10Glaser R, Glick H A, Herrmann H C ,et al. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitots for acute coronary syndromes a cost-effectiveness analysis [ J ]. Journal of the American College of Cardiology, 2006 fi-7 ( 3 ) : 529-537.

引证文献4

二级引证文献6

心血管病学进展
2012年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部